Selective decrease of hypothalamic noradrenaline by cysteamine.
In dose studies, cysteamine pretreatment in a dose of 200 mg/kg or 300 mg/kg (subcutaneously, s.c.) markedly decreased the hypothalamic noradenaline content, but did not influence the dopamine and serotonin contents. In time studies, pretreatment with cysteamine in a dose of 300 mg/kg (s.c.) led to markedly decreased hypothalamic noradrenaline contents 4 hr, 8 hr and 12 hr after treatment. These results suggest that cysteamine treatment selectively decreases the hypothalamic noradrenaline content in dose- and time-related manners.
D000818:Animals; D003543:Cysteamine / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D007031:Hypothalamus / Q000378:metabolism*; D008297:Male; D009638:Norepinephrine / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D013997:Time Factors
D012701:Serotonin; D003543:Cysteamine; D004298:Dopamine; D009638:Norepinephrine